Evidence map›Paper›PMID 30448597›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2019

Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.

Robert Battat, Marjolijn Duijvestein, Niels Vande Casteele, Siddharth Singh, Parambir S Dulai, Mark A Valasek, Larry Mimms, Judson McFarland, Kelly D Hester, Mark Renshaw and 3 more

Open access · greenAbstract read
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Management of bile acid diarrhea in Italy: a survey.Internal and emergency medicine · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Usefulness of colestimide for diarrhea in postoperative Crohn's disease.JGH open : an open access journal of gastroenterology and hepatology · 2022
    Article
  9. Review
  10. Review
  11. Bile Acid Diarrhea in Adults and Adolescents.Neurogastroenterology and motility · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. United European gastroenterology journal · 2020
    Article
  16. The Role of Bile Acids in Chronic Diarrhea.The American journal of gastroenterology · 2020
    Review
  17. Article
  18. Review
  19. Review
  20. UEG Week 2019 Oral Presentations.United European gastroenterology journal · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Robert BattatDivision of Gastroenterology, University of California San Diego, La Jolla, California.
Marjolijn DuijvesteinDivision of Gastroenterology, University of California San Diego, La Jolla, California; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands.
Niels Vande CasteeleDivision of Gastroenterology, University of California San Diego, La Jolla, California.
Siddharth SinghDivision of Gastroenterology, University of California San Diego, La Jolla, California.
Parambir S DulaiDivision of Gastroenterology, University of California San Diego, La Jolla, California.
Mark A ValasekDepartment of Pathology, University of California San Diego, La Jolla, California.
Larry MimmsPrometheus Laboratories Inc, San Diego, California.
Judson McFarlandPrometheus Laboratories Inc, San Diego, California.
Kelly D HesterPrometheus Laboratories Inc, San Diego, California.
Mark RenshawPrometheus Laboratories Inc, San Diego, California.
Anjali JainPrometheus Laboratories Inc, San Diego, California.
William J SandbornDivision of Gastroenterology, University of California San Diego, La Jolla, California.
Brigid S BolandDivision of Gastroenterology, University of California San Diego, La Jolla, California. Electronic address: bboland@ucsd.edu.
University of California San Diego · USPrometheus Biosciences (United States) · USAmsterdam UMC Location University of Amsterdam · NL

Funding

UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel DiseasesK23DK117058 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2018 to 2022
$971k
NCATS NIH HHS KL2 TR001444NIDDK NIH HHS K23 DK117058
6 · The paper itself

Abstract

BACKGROUND &

aimsPatients with Crohn's disease (CD) often have bile acid diarrhea (BAD), due to bile acid malabsorption following ileal resection (IR). Bile acid malabsorption increases production of 7α-hydroxy-4-cholesten-3-one (C4), a bile acid precursor. We investigated relationships between serum concentrations of C4 and BAD in patients with CD.

methodsWe collected demographic data, serum samples, and information on the presence of diarrhea (>3 liquid bowel movements/day), as well as clinical, endoscopic, and histologic scores from 26 patients with CD and IR, 21 patients with CD without IR, and 37 patients with ulcerative colitis (UC). We compared serum concentrations of C4 and fibroblast growth factor 19 (FGF19) between groups. We performed area under the receiver operating characteristic curve (AUROC) analysis to identify the optimal cutoff C4 concentrations for the diagnosis of diarrhea attributable to bile acid malabsorption (BAD), defined as diarrhea and a serum concentration of FGF19 <60 pg/mL.

resultsPatients with UC had a median serum C4 concentration of 11.8 ng/mL, whereas patients with CD and IR with ileitis (documented endoscopically) had a median concentration of 100.0 ng/mL (P compared to UC < .0001) and patients with CD and IR without ileitis had a median concentration of 51.6 ng/mL (P compared to UC < .001). Patients with CD without IR did not have a significantly higher median concentration of C4 than patients with UC (P = .71), regardless of ileitis (P = .34). When endoscopic findings were confirmed histologically, similar results were found to analyses using endoscopic findings alone. A higher proportion of patients with active UC had diarrhea (72.0% vs 0 patients with inactive UC; P < .001), but their median concentrations of C4 did not differ significantly from that of patients with inactive UC (12.1 ng/mL vs 9.7 ng/mL; P = .3). A cutoff concentration of C4 of 48.3 ng/mL or greater identified patients with diarrhea attributable to bile acid malabsorption with 90.9% sensitivity, 84.4% specificity, and an AUROC 0.94. A significantly higher proportion of patients with concentrations of C4 above this cutoff had BAD (50.0%) than below this cutoff (1.8%) (P < .001). When we analyzed only patients with diarrhea, a C4 cutoff of 48.3 ng/mL identified those with low FGF19 concentrations (<60 pg/mL) with 91% sensitivity and 95.5% specificity (AUROC, 0.99). Above this cutoff, 83.3% of patients had a serum concentration of FGF19 <60 pg/mL compared to 4.5% below this threshold (P < .0001). C4 concentrations correlated with the number of daily bowel movements (r = 0.41; P = .004) and correlated inversely with FGF19 concentrations (r = -0.72; P<.0001).

conclusionWe observed significantly increased serum concentrations of C4 in patients with CD with IR, compared to patients with UC. A cutoff concentration of C4 above 48.3 ng/mL identifies patients with diarrhea likely attributable to bile acid malabsorption (BAD) with an AUROC value of 0.94. Increased serum levels of bile acid precursors identify patients with diarrhea and a low serum concentration of FGF19, and concentrations of C4 correlate with daily liquid bowel movements and correlate inversely with FGF19 concentrations. C4 may be a biomarker to identify patients with diarrhea attributable to bile acid malabsorption.

Indexed as

AdultBile Acids and SaltsBiomarkersCholestenonesComplement C4Crohn DiseaseDiarrheaFemaleFibroblast Growth FactorsHumansIleumMaleSteatorrhea7 alpha-hydroxy-4-cholesten-3-oneBile Acids and SaltsBiomarkersCholestenonesComplement C4FGF19 protein, humanFibroblast Growth FactorsInflammatory Bowel DiseasesMonitoringNoninvasive TestSurgical Complications

Identifiers

PMID30448597
PMCPMC6520204
OpenAlexW2901362128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.